Boston, MA -- (SBWIRE) -- 02/06/2014 -- BMI View: Cambodia will continue to underperform other pharmaceutical markets in the Asia Pacific region, given its low health and pharmaceutical expenditure as well as the rampant corruption in the country. We highlight that, given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over the counter products than innovative pharmaceuticals.
Headline Expenditure Projections
- Pharmaceuticals: KHR721.1bn (US$170mn) in 2012 to KHR788.8bn (US$200mn) in 2013; +9.4% in local currency terms and +10.0% in US dollar terms. Forecast broadly in line with Q413.
- Healthcare: KHR3,168.4bn (US$780mn) in 2012 to KHR3,382.1bn (US$84mn) in 2013; +6.7% in local currency terms and +7.4% in US dollar terms. Forecast broadly in line with Q413.
View Full Report Details and Table of Contents
Risk/Reward Rating: Cambodia's Pharmaceutical Risk/Reward Rating (RRR) score for Q114 is 32.4 out of the maximum 100 in our newly improved RRR system. The country scored below average for almost all indicators and sub-indicators including overall market expenditure, sector value growth and pensionable population. Consequently with this low score, Cambodia ranks second-to-last out of the 19 key markets in Asia Pacific, ahead of Myanmar.
Key Trends And Developments
- In December 2013, Cambodia Daily reported that the Japanese government will open an internationalstandard hospital in Phnom Penh. The construction of the medical facility, which will include state-ofthe- art medical technology and highly skilled doctors, nurses and surgeons, is contingent on the approval of a Japanese plan by the Cambodian government. The project was announced by Japan's Prime Minister Shinzo Abe on his visit to Cambodia in November. The new critical-care centre will be the first of its kind in Cambodia and is scheduled to become operational in 2015. The medical facility will be part of the Kitahara International Hospital group that is widely known for its neurosurgical treatment. The location of the hospital is yet to be decided and is expected to be funded primarily by private investors.
- In November 2013, the World Health Organization (WHO) requested the Global Fund to allocate US $15mn of the total US$100mn grant to stop the spread of resistance to Artemisinin-based Combination Therapies (ACTs) currently used to fight malaria in Cambodia. The Global Fund's US$100mn was allocated as an emergency response to combat resistance to malaria. According to Eva Christophel, the WHO's regional malaria adviser in Manila, the US$15mn requested for Cambodia would partly be used to move the WHO's regional office for fighting ACT resistance from Bangkok to Phnom Penh.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Malaysia Pharmaceuticals & Healthcare Report Q1 2014
- Russia Pharmaceuticals & Healthcare Report Q1 2014
- Sweden Pharmaceuticals & Healthcare Report Q1 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q1 2014
- Estonia Pharmaceuticals & Healthcare Report Q1 2014
- Qatar Pharmaceuticals & Healthcare Report Q1 2014
- Kenya Pharmaceuticals & Healthcare Report Q1 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q1 2014
- Serbia Pharmaceuticals & Healthcare Report Q1 2014
- Algeria Pharmaceuticals & Healthcare Report Q1 2014